key: cord-0816225-65t5yy7g
authors: Siniorakis, Eftychios; Arvanitakis, Spyridon; Katsianis, Antonios; Elkouris, Maximilianos
title: Atrial fibrillation and flutter in patients hospitalized for COVID‐19: The challenging role of digoxin
date: 2021-02-01
journal: J Cardiovasc Electrophysiol
DOI: 10.1111/jce.14894
sha: 2fca4ed73be4660d108ac1d0292626e005b53bd6
doc_id: 816225
cord_uid: 65t5yy7g

nan

To the Editor,

We read with interest the article by Peltzer et al. 1 referring to the occurrence of atrial fibrillation and flutter (AF/f) in patients hospitalized with coronavirus disease ). An incidence of 16% was observed, while 60% of this arrhythmia was of new onset. The manifestation of AF/f was followed by high morbidity and mortality, which were further aggravated when markers of cardiac injury and inflammation were present, suggesting an imminent cytokine storm. The study was retrospective; thus, information regarding the therapeutic treatment of AF/f was missing. However, in an illustrated paradigm, the treatment 

Outcomes and mortality associated with atrial arrhythmias among patients hospitalized with COVID-19

Characterization of the Na, K pump current in atrial cells from patients with and without chronic atrial fibrillation

Novel therapeutic applications of cardiac glycosides

ATP1A1-mediated Src signaling inhibits coronavirus entry into host cells

Classical drug digitoxin inhibits influenza cytokine storm, with implications for Covid-19 therapy

Oleadrin suppresses activation of nuclear transcription factor-kappa B activator protein-1, and C-JunNH2-terminal kinase

Cardiac glycosides in cancer research and cancer therapy

Trials of anti-tumor necrosis factor therapy for COVID-19 are urgently needed